GlassScriptPhysician profile
Neil N Phung
NPI 1063523223
$4,368.35
in general payments reported to CMS, 2019-2025
27 companies · $582 in 2025
The $582 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $934 · 2020: $463 · 2021: $562 · 2022: $610 · 2023: $489 · 2024: $729 · 2025: $582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,780 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,779.56 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,138.28 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $475.45 | 2021-2025 | Verquvo |
| Sanofi-Aventis U.S. LLC | $334.28 | 2019-2024 | |
| Itamar Medical INC | $308.41 | 2022-2025 | Watchpatone |
| Novartis Pharmaceuticals Corporation | $291.09 | 2019-2024 | |
| Pfizer INC. | $238.70 | 2019-2024 | |
| Edwards Lifesciences Corporation | $180.46 | 2019-2025 | Inspiris Resilia Aortic Valve |
| Amarin Pharma, INC. | $179.96 | 2019-2021 | |
| Amgen INC. | $176.86 | 2021-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $161.14 | 2019-2023 | Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.44 | 2019-2024 | Jardiance |
| Heartflow, INC. | $106.25 | 2021-2025 | |
| Philips North America LLC | $103.54 | 2024 | (Ck7) Extended Holter, (Ck4) Mcot |
| Cleerly, INC. | $80.23 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Astrazeneca Pharmaceuticals LP | $72.25 | 2019-2024 | Farxiga |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $70.26 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $60.81 | 2021-2023 | Camzyos, Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $41.55 | 2024 | |
| Novo Nordisk INC | $40.34 | 2025 | Ozempic |
| Baxter Healthcare | $36.23 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Glaxosmithkline, LLC. | $25.21 | 2025 | Arexvy |
| Braemar Manufacturing, LLC | $22.55 | 2019 | |
| Gilead Sciences, INC. | $21.50 | 2019 | |
| Abbott Laboratories | $20.65 | 2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Regeneron Healthcare Solutions, INC. | $15.38 | 2019 | |
| Tactile Systems Technology INC | $13.81 | 2022 | |
| Bardy Diagnostics, INC. | $12.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Phung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.